HUMANIN VS MOTS-c
Humanin and MOTS-c are the two most-cited mitochondrial-derived peptides (MDPs), discovered roughly 14 years apart. Humanin is a 24-aa peptide encoded within the mitochondrial 16S rRNA gene · characterized first for anti-apoptotic neuroprotection against amyloid-beta (Hashimoto 2001). MOTS-c is a 16-aa peptide encoded within the mitochondrial 12S rRNA · characterized for AMPK activation and insulin-sensitivity (Lee 2015). Same family, different functions.
SIDE BY SIDE
WHICH IS BETTER · BY GOAL
Hashimoto 2001 established humanin as a rescue factor against amyloid-beta toxicity in neuronal cell models. MOTS-c is not specifically framed as a neuroprotective compound.
Reynolds 2021 (Nat Commun, PMID 33473109) reported improved treadmill performance and grip strength in aged mice with MOTS-c. Humanin not specifically studied as an exercise mimetic.
MOTS-c is the canonical AMPK-activating MDP. Humanin's primary mechanism is anti-apoptotic via BAX, not AMPK.
Humanin's primary characterized mechanism is BAX inhibition, blocking the intrinsic apoptosis pathway. MOTS-c does not have characterized BAX activity.
Both peptides have circulating levels that correlate with longevity in human population studies (humanin: Lee 2015 reviews of centenarian cohorts; MOTS-c: Du 2018 / Lu 2019). Magnitude varies by assay and population.
STACKING NOTE
Humanin + MOTS-c covers two non-overlapping branches of mitochondrial-derived peptide biology (anti-apoptotic + AMPK-activating). No published RCT studies the combination, but mechanistic complementarity is the basis for any Cellular Bioenergetics MDP-stack research framing.
SOURCED FROM GIGACOMPOUNDS
Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

